Oyster Point Pharma, Inc.
OYSTDelisted Jan 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001720725
Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
Q2 2022 vs. Q1 2022
How the institutions holding Oyster Point Pharma, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 72 | 1 | 61 | −10 |
| Shares | 21.2M | 1.37K | 20.2M | −928.1K (−4.4%) |
| Value | $246.2M | $16.0K | $87.6M | −$158.6M (−64.4%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Oyster Point Pharma, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 210,200 | $910.0K | 0.04% |
| Millennium Management LLC | 134,638 | $583.0K | 0.00% |
| Susquehanna International Group, LLP | 57,354 | $248.0K | 0.00% |
| Bridgeway Capital Management, LLC | 40,000 | $173.0K | 0.00% |
| Ergoteles LLC | 34,752 | $150.0K | 0.00% |
| Kestra Advisory Services, LLC | 11,900 | $52.0K | 0.00% |
| Cherry Creek Investment Advisors, Inc. | 10,000 | $43.0K | 0.03% |
| GPS Wealth Strategies Group, LLC | 2,134 | $9.00K | 0.00% |
| Federated Hermes, Inc. | 112 | $1.00K | 0.00% |
| Wells Fargo & Company | 86 | $0 | 0.00% |
| Credit Suisse AG | 6 | $0 | 0.00% |
Sold out (21)
Institutions that held Oyster Point Pharma, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| First Manhattan Co | 260,553 | $3.03M |
| Nuveen Asset Management, LLC | 107,352 | $1.25M |
| Baker Bros. Advisors LP | 61,424 | $715.0K |
| Oak Ridge Investments LLC | 40,326 | $469.0K |
| Bank of New York Mellon Corp | 39,209 | $456.0K |
| Charles Schwab Investment Management Inc | 33,139 | $386.0K |
| Alps Advisors Inc | 27,366 | $319.0K |
| Jacobs Levy Equity Management, Inc | 20,537 | $239.0K |
| Alliancebernstein L.P. | 14,900 | $173.0K |
| Rhumbline Advisers | 13,531 | $158.0K |
| Vontobel Holding Ltd. | 10,303 | $120.0K |
| Nwam LLC | 10,000 | $116.0K |
| Deutsche Bank AG | 6,202 | $72.0K |
| American International Group, Inc. | 5,516 | $64.0K |
| California State Teachers Retirement System | 4,794 | $56.0K |
| Amalgamated Bank | 1,366 | $16.0K |
| Legal & General Group Plc | 884 | $10.0K |
| Quantbot Technologies LP | 900 | $10.0K |
| Allspring Global Investments Holdings, LLC | 722 | $8.00K |
| Ameritas Investment Partners, Inc. | 485 | $6.00K |
| US Bancorp | 307 | $4.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Oyster Point Pharma, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 1,366 | $16.0K |